← Back to Search

Virus Therapy

MTG201 for Mesothelioma

Phase 2

Waitlist Available

Led By Bryan Burt, MD

Research Sponsored by Momotaro-Gene Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new treatment for a type of cancer called mesothelioma. The treatment involves injecting a virus into the tumor, and then giving the patient infusions of a drug called nivolumab.

Eligible Conditions

Mesothelioma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective response rate (ORR)

Secondary outcome measures

duration of response (DUR)

progression free survival (PFS)

Other outcome measures

Incidence of adverse events

change from baseline in liver transaminases

Trial Design

1Treatment groups

Experimental Treatment

Group I: MTG201 plus NivolumabExperimental Treatment2 Interventions

Single arm, open-label, patients receive both MTG201 and nivolumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nivolumab Injection [Opdivo]

2018

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Baylor College of MedicineOTHER

1,001 Previous Clinical Trials

6,002,240 Total Patients Enrolled

3 Trials studying Mesothelioma

83 Patients Enrolled for Mesothelioma

Momotaro-Gene Inc.Lead Sponsor

2 Previous Clinical Trials

28 Total Patients Enrolled

Synteract, Inc.Industry Sponsor

20 Previous Clinical Trials

5,890 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical research the inaugural exploration of its type?

"MTG201 has been under investigation since 2012, when the first study was funded by Ono Pharmaceutical Co. Ltd., and involved 659 participants. After achieving Phase 1 & 2 drug approval, MTG201 is now being studied in 718 studies across 2356 cities and 49 nations worldwide."

Answered by AI

Have any other clinical tests been conducted with MTG201?

"Presently, there are 82 Phase 3 studies and a total of 718 clinical trials that are assessing the efficacy of MTG201. Most experiments occur in Basel, BE but it is being explored at 40285 different sites."

Answered by AI

What afflictions is MTG201 typically employed to alleviate?

"MTG201 is frequently prescribed for patients with malignant neoplasms, as well as conditions like metastatic esophageal adenocarcinoma, squamous cell carcinoma and inoperable melanomas."

Answered by AI

Are there still opportunities to join this research endeavor?

"This clinical trial has ended its recruitment efforts, as evidenced by the posting and update dates of 8/15/2019 and 6/13/2022 respectively. If you are still looking for potential studies to participate in, there are 152 trials searching for mesothelioma patients and 718 recruiting individuals taking part in MTG201 research."

Answered by AI

Has MTG201 been granted authorization by the Food and Drug Administration?

"MTG201's safety rating on the scale of 1 to 3 is a 2 due to its current standing as a Phase 2 clinical trial, suggesting that it has been deemed safe by previous data but there isn't any evidence for efficacy yet."

Answered by AI

How many participants will be included in the clinical trial?

"This study has concluded its recruitment process and is no longer accepting patients. First posted on August 15th, 2019 with a last update of June 13th 2022; nonetheless, there are now 152 different clinical trials searching for mesothelioma participants as well as 718 recruiting MTG201 trial enrollees."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

2019. "MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04013334.

All > Mesothelioma